Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
AstraZeneca
Express Scripts
Dow
Colorcon

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,746,429

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,746,429 protect, and when does it expire?

Patent 6,746,429 protects OTREXUP and is included in one NDA.

This patent has thirteen patent family members in eight countries.

Summary for Patent: 6,746,429
Title: Needle assisted jet injector
Abstract:A needle assisted jet injector and method for jet injecting medicament are disclosed. In one embodiment of the injector, the needle is retractably located within an injector nozzle assembly. Upon activation of the force generating source, a portion of the needle extends past the nozzle assembly and penetrates the outer layer of skin to deliver the medicament via jet injection to a deeper region. After activation, the needle retracts back into the nozzle assembly. In another embodiment, the needle is fixed to the end of the nozzle assembly. In both embodiments, the length of the portion of the needle that penetrates the skin is less than 5 mm.
Inventor(s): Sadowski; Peter L. (Woodbury, MN), DeBoer; David M. (Brighton, MI), Berman; Claude L. (Ypsilanti, MI), Lesch, Jr.; Paul R. (Lexington, MN), Holland; Margaret L. (Rochester, NY)
Assignee: Antares Pharma, Inc. (Minneapolis, MN)
Application Number:09/779,603
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,746,429
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 6,746,429

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Medtronic
Baxter
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.